Press Releases
ROME Therapeutics today announced that members of the ROME Senior Leadership Team will participate in the TD Cowen 44th Annual Health Care Conference.
ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer
ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery
ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors
Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development
ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease
ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research
ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors
ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS
ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy
ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery
ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.
ROME Therapeutics announces that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies
ROME Therapeutics Appoints Drug Discovery Veteran Dennis Zaller, Ph.D., as Chief Scientific Officer
ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome